Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia.
Rozalyn L RodwinJohn A KairallaEmily HibbittsMeenakshi DevidasMoira K WhitleyCaroline E MohrmannReuven J SchoreElizabeth RaetzNaomi J WinickStephen P HungerMignon L LohMarilyn J HockenberryAnne L AngiolilloKirsten K NessNina S Kadan-LottickPublished in: Journal of the National Cancer Institute (2022)
CIPN is prevalent early in B-ALL therapy and persists at least 12 months posttherapy. Most outcomes did not differ between treatment groups despite reduction in vincristine frequency. Children with B-ALL should be monitored for CIPN, even with reduced vincristine frequency.